Steminent Biotherapeutics Inc. (TPEX:7729)
Taiwan
· Delayed Price · Currency is TWD 80.20
-1.10 (-1.35%)
At close: Mar 9, 2026
Steminent Biotherapeutics Company Description
Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States.
It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington’s disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke.
The company was founded in 2009 and is based in Taipei, Taiwan.
Steminent Biotherapeutics Inc.
| Country | Taiwan |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Ling-Mei Wang |
Contact Details
Address: No. 12, Wenhu Street Taipei, 11445 Taiwan | |
| Phone | 886 2 2627 9216 |
| Website | steminent.com |
Stock Details
| Ticker Symbol | 7729 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0007729006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ling-Mei Wang | Chairman and GM |
| Yi-Chih Lo | Director of Finance and Corporate Governance Officer and Accounting Supervisor |
| Jonathan Ko | Senior Vice President |